203 related articles for article (PubMed ID: 7544393)
1. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.
Fargeas CA; Truneh A; Reddy M; Hurle M; Sweet R; Sékaly RP
J Exp Med; 1995 Sep; 182(3):667-75. PubMed ID: 7544393
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain.
Guo Y; Wu Y; Zhao M; Kong XP; Liu Y
J Exp Med; 1995 Apr; 181(4):1345-55. PubMed ID: 7535334
[TBL] [Abstract][Full Text] [Related]
3. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28.
Peach RJ; Bajorath J; Naemura J; Leytze G; Greene J; Aruffo A; Linsley PS
J Biol Chem; 1995 Sep; 270(36):21181-7. PubMed ID: 7545666
[TBL] [Abstract][Full Text] [Related]
4. Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis.
Truneh A; Reddy M; Ryan P; Lyn SD; Eichman C; Couez D; Hurle MR; Sekaly RP; Olive D; Sweet R
Mol Immunol; 1996 Feb; 33(3):321-34. PubMed ID: 8649453
[TBL] [Abstract][Full Text] [Related]
5. Identification of conserved amino acids in murine B7-1IgV domain critical for CTLA4/CD28:B7 interaction by site-directed mutagenesis: a novel structural model of the binding site.
Guo Y; Wu Y; Kong X; Liu Y
Mol Immunol; 1998 Mar; 35(4):215-25. PubMed ID: 9736337
[TBL] [Abstract][Full Text] [Related]
6. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R
Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620
[TBL] [Abstract][Full Text] [Related]
7. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells.
Caux C; Vanbervliet B; Massacrier C; Azuma M; Okumura K; Lanier LL; Banchereau J
J Exp Med; 1994 Nov; 180(5):1841-7. PubMed ID: 7525840
[TBL] [Abstract][Full Text] [Related]
8. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions.
Greene JL; Leytze GM; Emswiler J; Peach R; Bajorath J; Cosand W; Linsley PS
J Biol Chem; 1996 Oct; 271(43):26762-71. PubMed ID: 8900156
[TBL] [Abstract][Full Text] [Related]
9. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
Lane P
Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
[TBL] [Abstract][Full Text] [Related]
10. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.
Metzler WJ; Bajorath J; Fenderson W; Shaw SY; Constantine KL; Naemura J; Leytze G; Peach RJ; Lavoie TB; Mueller L; Linsley PS
Nat Struct Biol; 1997 Jul; 4(7):527-31. PubMed ID: 9228944
[TBL] [Abstract][Full Text] [Related]
11. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.
van der Merwe PA; Bodian DL; Daenke S; Linsley P; Davis SJ
J Exp Med; 1997 Feb; 185(3):393-403. PubMed ID: 9053440
[TBL] [Abstract][Full Text] [Related]
12. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
[TBL] [Abstract][Full Text] [Related]
13. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.
Freeman GJ; Borriello F; Hodes RJ; Reiser H; Gribben JG; Ng JW; Kim J; Goldberg JM; Hathcock K; Laszlo G
J Exp Med; 1993 Dec; 178(6):2185-92. PubMed ID: 7504059
[TBL] [Abstract][Full Text] [Related]
14. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
Freeman GJ; Gribben JG; Boussiotis VA; Ng JW; Restivo VA; Lombard LA; Gray GS; Nadler LM
Science; 1993 Nov; 262(5135):909-11. PubMed ID: 7694363
[TBL] [Abstract][Full Text] [Related]
15. Interactions of CD80 and CD86 with CD28 and CTLA4.
Ellis JH; Burden MN; Vinogradov DV; Linge C; Crowe JS
J Immunol; 1996 Apr; 156(8):2700-9. PubMed ID: 8609386
[TBL] [Abstract][Full Text] [Related]
16. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
Peach RJ; Bajorath J; Brady W; Leytze G; Greene J; Naemura J; Linsley PS
J Exp Med; 1994 Dec; 180(6):2049-58. PubMed ID: 7964482
[TBL] [Abstract][Full Text] [Related]
17. B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.
Zheng P; Wu Y; Guo Y; Lee C; Liu Y
Proc Natl Acad Sci U S A; 1998 May; 95(11):6284-9. PubMed ID: 9600957
[TBL] [Abstract][Full Text] [Related]
18. Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematosus (SLE) patients.
García-Cózar FJ; Molina IJ; Cuadrado MJ; Marubayashi M; Peña J; Santamaría M
Clin Exp Immunol; 1996 Apr; 104(1):72-9. PubMed ID: 8603537
[TBL] [Abstract][Full Text] [Related]
19. Blockade of CD28/B7 interaction suppresses allergic eosinophilic inflammation in mice.
Kasai M; Kumano K; Kurasawa K; Nakao A; Saito Y; Iwamoto I
Int Arch Allergy Immunol; 1998 Sep; 117 Suppl 1():14-9. PubMed ID: 9758890
[TBL] [Abstract][Full Text] [Related]
20. CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis.
Xu X; Dennett P; Zhang J; Sherrard A; Zhao Y; Masubuchi T; Bui JD; Chen X; Hui E
J Exp Med; 2023 Jul; 220(7):. PubMed ID: 37042938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
